Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald de Wit

Showing results (41-50 of 204) with videos related to

Pageof 21
Sort By:
The Lancet. Oncology|November 3, 2007
Bleomycin and scuba diving: where is the harm?Ronald de Wit, Stefan Sleijfer, Stan B Kaye, et al.
European Urology|October 15, 2013
The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancerGregory R Pond, Guru Sonpavde, Ronald de Wit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 studyDominik R Berthold, Gregory R Pond, Martin Roessner, et al.
International Journal of Molecular Sciences|March 29, 2023
A Compendium of AR Splice Variants in Metastatic Castration-Resistant Prostate CancerKhrystany T Isebia, Martijn P Lolkema, Guido Jenster, et al.
European Urology Oncology|February 16, 2020
Liquid Biopsies to Select Patients for Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: A Systematic ReviewIngeborg E de Kruijff, Nick Beije, John W M Martens, et al.
European Journal of Cancer (Oxford, England : 1990)|March 6, 2007
Multidimensional fatigue and its correlates in hospitalised advanced cancer patientsMichael A Echteld, Jan Passchier, Saskia Teunissen, et al.
European Urology Focus|March 13, 2026
Clinical Trial Protocol for the Apa/Enza-short Study: A Randomized Nationwide Study of Shortened 12-Month Duration of Androgen Receptor Signaling Agent in Combination With Androgen Deprivation Therapy in Patients With Metastatic Low-volume Castration-sensitive Prostate CancerMahtab Hamidikia, Tanja C van Dijk, John W M Martens, et al.
European Urology|November 5, 2017
Reply to Nelson Martinez Merizalde Balarezo, Mark Monroe Rivera, and Romina A. Tejada's Letter to the Editor re: Maud Rijnders, Ronald de Wit, Joost L. Boormans, Martijn P.J. Lolkema, Astrid A.M. van der Veldt. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers. Eur Urol. 2017;72:411-23. Beyond the Survival Rate, Health-related Quality of Life is ImportantMaud Rijnders, Ronald de Wit, Joost L Boormans, et al.
European Urology|June 25, 2017
Systematic Review of Immune Checkpoint Inhibition in Urological CancersMaud Rijnders, Ronald de Wit, Joost L Boormans, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|April 2, 2021
Cross-resistance and drug sequence in prostate cancerStefan A J Buck, Stijn L W Koolen, Ron H J Mathijssen, et al.
Pageof 21

Showing results (41-50 of 204) with videos related to

Sort By:
Pageof 21
The Lancet. Oncology|November 3, 2007
Bleomycin and scuba diving: where is the harm?Ronald de Wit, Stefan Sleijfer, Stan B Kaye, et al.
European Urology|October 15, 2013
The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancerGregory R Pond, Guru Sonpavde, Ronald de Wit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 studyDominik R Berthold, Gregory R Pond, Martin Roessner, et al.
International Journal of Molecular Sciences|March 29, 2023
A Compendium of AR Splice Variants in Metastatic Castration-Resistant Prostate CancerKhrystany T Isebia, Martijn P Lolkema, Guido Jenster, et al.
European Urology Oncology|February 16, 2020
Liquid Biopsies to Select Patients for Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: A Systematic ReviewIngeborg E de Kruijff, Nick Beije, John W M Martens, et al.
European Journal of Cancer (Oxford, England : 1990)|March 6, 2007
Multidimensional fatigue and its correlates in hospitalised advanced cancer patientsMichael A Echteld, Jan Passchier, Saskia Teunissen, et al.
European Urology Focus|March 13, 2026
Clinical Trial Protocol for the Apa/Enza-short Study: A Randomized Nationwide Study of Shortened 12-Month Duration of Androgen Receptor Signaling Agent in Combination With Androgen Deprivation Therapy in Patients With Metastatic Low-volume Castration-sensitive Prostate CancerMahtab Hamidikia, Tanja C van Dijk, John W M Martens, et al.
European Urology|November 5, 2017
Reply to Nelson Martinez Merizalde Balarezo, Mark Monroe Rivera, and Romina A. Tejada's Letter to the Editor re: Maud Rijnders, Ronald de Wit, Joost L. Boormans, Martijn P.J. Lolkema, Astrid A.M. van der Veldt. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers. Eur Urol. 2017;72:411-23. Beyond the Survival Rate, Health-related Quality of Life is ImportantMaud Rijnders, Ronald de Wit, Joost L Boormans, et al.
European Urology|June 25, 2017
Systematic Review of Immune Checkpoint Inhibition in Urological CancersMaud Rijnders, Ronald de Wit, Joost L Boormans, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|April 2, 2021
Cross-resistance and drug sequence in prostate cancerStefan A J Buck, Stijn L W Koolen, Ron H J Mathijssen, et al.
Pageof 21